Krystal Biotech, Inc. KRYS announced initial clinical data updates on its two inhaled genetic medicine pipeline candidates, ...

It’s been a while since I wrote about nutrition related to alpha-1 antitrypsin deficiency (AATD). Few studies have been done on the subject, as the condition is a relatively new discovery. However, as ...

Alpha-1 antitrypsin deficiency (AATD) is a genetic disorder associated with liver disease, ranging from fibrosis to ...

At a recent support group meeting for alpha-1 antitrypsin deficiency (AATD) patients, someone asked me a question I wasn’t expecting. He asked if I thought coffee was good for AATD patients. I did a ...

KRRO-110 is developed from Korro’s ribonucleic acid editing platform. Credit: Gorodenkoff/Shutterstock. Korro Bio has secured approvals in Australia to commence the ...

Alpha-1 antitrypsin deficiency (AATD) is a genetic disorder associated with liver disease, ranging from fibrosis to hepatocellular carcinoma. The disease remains asymptomatic until its final ...

Introduction Altered complement component 3 (C3) activation in patients with alpha-1 antitrypsin (AAT) deficiency (AATD) has been reported. To understand the potential impact on course of inflammation ...

mezagitamab, an investigational anti-CD38 antibody providing rapid, selective and sustained depletion of disease-causing ...

Shares in Wave Life Sciences rose by 74% after it reported clinical data with a pioneering new RNA-editing therapy for alpha-1 antitrypsin deficiency (AATD). Wave claims this is the first clinical ...

The following is a summary of “Higher healthcare cost and utilization before and after diagnosis of AATD in the United States,” published in the November 2024 issue of Pulmonology by Blanchette et al.

Korro Bio has secured approvals in Australia to commence the two-part Phase I/IIa REWRITE trial of its investigational product, KRRO-110, aimed at treating alpha-1 antitrypsin deficiency (AATD).